Autoimmune nodopathies have been distinguished from CIDP in recent years because patients with autoantibodies against nodal and paranodal molecules, such as neurofascin 155 (NF155), contactin 1 (CNTN1), contactin‐associated protein 1 (Caspr1), and neurofascin 186 (NF186), have specific clinical presentations [2]. This evidence concerns the gene CNTNAP1 and chronic inflammatory demyelinating polyradiculoneuropathy.